Published in Obesity and Diabetes Week, December 27th, 2004
The letter outlines the conditions for marketing approval, which include a submission of additional safety data.
YM087, generic drug conivaptan hydrochloride, is an injectable dual V1a/V2 vasopressin receptor antagonist. It increases blood sodium levels in patients with euvolemic and hypervolemic hyponatremia by increasing excretion of free water without increasing the sodium output...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.